Home > Browse Issues > Vol.39 No.2
Current Status and Future Prospect on CAR-T Cell Therapy for Malignant Tumors
Liu Xiaojun1,2,3, Zhao Da1,2,3, Bai Zhongtian2,3,4, Li Xun2,3,4*
1Division of Medical Oncology, The First Hospital of Lanzhou University, Lanzhou 730000, China;
2Hepatopancreatobiliary Surgery Institute of Gansu Province, Lanzhou 730000, China;
3Clinical Medical College Cancer Center of Lanzhou University, Lanzhou 730000, China;
4The Second Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, China
2Hepatopancreatobiliary Surgery Institute of Gansu Province, Lanzhou 730000, China;
3Clinical Medical College Cancer Center of Lanzhou University, Lanzhou 730000, China;
4The Second Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, China
Abstract: Chimeric antigen receptor (CAR) refers to a class of genetically-engineered antibodies，consisting of single chain fragment variable， co-stimulatory molecules and T cell signal transducing molecule.Whole exome sequencing (WES) is a newly-developed strategy to identify tumor antigens and this approach has advantages over the traditional serological analysis of expression cDNA libraries (SEREX). Recently， several clinical trials have reported some promising benefits of using the CAR-T cell therapy in the treatment of a variety of cancers including solid malignant tumors， although considerable concerns and challenges have been raised. This review aims to summarize the basic concept， critical strategies and current challenges involved in the deployment of CAR-T cell therapy for malignant tumors.
CN
EN